Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 55

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 2
Chunk 55
---
accine modality (“PLACCINE”). The provisional patent covers a family of novel composition of multi-cistronic vectors and
polymeric nanoparticles that comprise the PLACCINE DNA vaccine platform technology for preventing or treating infectious agents that
have the potential for global pandemics, including the SARS-CoV-2 virus and its variations, using the Company’s TheraPlas platform
technology.

Imunon’s
PLACCINE DNA vaccine modality is characterized by a single mono-cistronic or multi-cistronic DNA plasmid vector expressing single or
multiple pathogen antigens delivered with a synthetic delivery system. We believe it is adaptable to creating vaccines for a multitude
of pathogens, including emerging pathogens leading to pandemics as well as infectious diseases that have yet to be effectively addressed
with current vaccine technologies. This flexible vaccine platform is well supported by an established supply chain to produce any plasmid
vector and its assembly into a respective vaccine formulation.

The
need for new vaccine technologies is urgent. Since 1980, more than 80 pathogenic viruses have been discovered, yet fewer than 4% have
a commercially available prophylactic vaccine. We have engaged with the Biomedical Advanced Research and Development Authority (“BARDA”),
a division of the U.S. Department of Health and Human Services, to consider certain pathogens BARDA has identified as the most urgent
and the most important.

PLACCINE
is an extension of the Company’s synthetic, non-viral TheraPlas delivery technology currently in development for the treatment
of late-stage ovarian cancer with IMNN-001. Imunon’s proprietary multifunctional DNA vaccine technology concept is built on the
flexible PLACCINE technology platform that is amenable to rapidly responding to the SARS-CoV-2 virus, as well as possible future mutations
of SARS-CoV-2, other future pandemics, emerging bioterrorism threats, and novel infectious diseases. Imunon’s extensive experience
with TheraPlas suggests that the PLACCINE-based nanoparticles are stable at storage temperatures of 4°C to 25°C, making vaccines
developed on this platform easily suitable for broad world-wide distribution.

Imunon’s
vaccine approach is designed to optimize the quality of the immune response dictating the efficiency of pathogen clearance and patient
recovery. Imunon has taken a multivalent approach in an effort to generate an even more robust immune response that not only results
in a strong neutralizing antibody